May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX
Alphamab bispecifics against checkpoints, pair of HER2 sites
In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing KN046 had a 12% overall response rate (ORR) in 25 evaluable patients with nasopharyngeal or non-small cell lung cancer who had progressed on prior checkpoint inhibitor treatment. The bispecific against PD-L1 and CTLA-4 also resulted in 10 cases of stable disease, yielding a 52% disease control rate (DCR). Median progression-free survival (PFS) was 2.69 months; median overall survival (OS) has not been reached.
In a second abstract, the company said the recommended Phase II doses of KN026, which binds two HER2 sites, led to a 32.1% ORR and a 76.8% DCR in a Phase I trial to treat metastatic breast cancer in patients previously treated with anti-HER2 therapy. Alphamab rose nearly 10% Thursday, gaining HK$1.60 to HK$18.62...